Glypican4 and CTRP5 in Metabolic Syndrome and the Effect of Exercise on These Adipokines

Effects of Exercise on Glypican4,CTRP3,5 and RBP4 Levels and Circulating Levels of These Adipokines in the Subjects With or Without Metabolic Syndrome

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01688622

Enrollment

Registered

2012-09-20

Start date

2012-07-31

Completion date

2012-09-30

Last updated

2012-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity

Brief summary

Glypican4, CTRP3, CTRP5 are emerging novel adipokines mediating obesity and inflammation related disorders. RBP4 and adiponectin are well known important adipokines. Therefore, we examine the circulating levels of theses adipokines in the subjects with or without metabolic syndrome. Furthermore, we tried to clarify the effect of exercise on the circulating these adipokines.

Interventions

BEHAVIORAL3months Exercise

training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Women between 30 and 60 years of age who had a body mass index (BMI) more than 25 kg/m2 * The subjects of metabolic syndrome and age, gender matched non metabolic syndrome among the participants of Korean SO Study (KSOS) study, which is an ongoing epidemiologic study supported by the Korea Science and Engineering Foundation

Exclusion criteria

* participants had a history of cardiovascular disease * any type of diabetes * stage 2 hypertension * malignant disease, severe renal, or hepatic disease * Subjects taking medications that might affect body weight or body composition

Design outcomes

Primary

Measure	Time frame
The changes of circulating adiponectin levels after 3 months exercise	baseline and 12weeks
The changes of circulating glypican4 levels after 3 months exercise	baseline and 12weeks
The changes of circulating CTRP3 levels after 3 months exercise	baseline and 12weeks
The changes of circulating CTRP5 levels after 3 months exercise	baseline and 12weeks
The changes of circulating RBP4 levels after 3 months exercise	baseline and 12weeks

Secondary

Measure	Time frame
Circulating glypican4 levels in the subjects with or without metabolic syndrome	baseline
Circulating CTRP3 levels in the subjects with or without metabolic syndrome	baseline
Circulating CTRP5 levels in the subjects with or without metabolic syndrome	baseline
Circulating RBP4 levels in the subjects with or without metabolic syndrome	baseline
Circulating adiponectin levels in the subjects with or without metabolic syndrome	baseline

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026